Halozyme Therapeutics, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $493.0 million (+39.2% year over year) and diluted EPS of $2.01. It usually reports 28–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 27, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Jan 28, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 28–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
493
+39.2%
|
247
+41.0%
|
2.01
+40.6%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
481
+47.7%
|
230
+39.2%
|
1.90
+42.9%
|
|
May 11, 2026
41 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
377
+42.2%
|
150
+27.1%
|
1.22
+31.2%
|
|
Jan 28, 2026
28 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
452
+51.6%
|
-142
-203.3%
|
-1.16
-209.1%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
354
+22.1%
|
175
+27.9%
|
1.43
+36.2%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
326
+40.8%
|
165
+77.1%
|
1.33
+84.7%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
265
+35.2%
|
118
+53.7%
|
0.93
+55.0%
|
|
Jan 8, 2025
8 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
298
+29.5%
|
137
+60.5%
|
1.06
+63.0%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- HALO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1159036
- Former names
- HALOZYME THERAPEUTICS INC (until Jul 3, 2019); GLOBAL YACHT SERVICES INC (until Mar 12, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.